ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization , 2021. Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021–2030. Available at: https://www.who.int/publications/i/item/9789240010352. Accessed May 12, 2023.
-
2.
World Health Organization , 2013. Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2020. Available at: https://apps.who.int/iris/handle/10665/78074. Accessed May 12, 2023.
-
3.
Institute for Health Metrics and Evaluation , 2019. Schistosomiasis: Level 3 Cause. Available at: https://www.healthdata.org/results/gbd_summaries/2019/schistosomiasis-level-3-cause. Accessed March 31, 2023.
-
4.
Montresor A , Mwinzi P , Mupfasoni D , Garba A , 2022. Reduction in DALYs lost due to soil-transmitted helminthiases and schistosomiasis from 2000 to 2019 is parallel to the increase in coverage of the global control programmes. PLoS Negl Trop Dis 16: e0010575.
-
5.
Gunda DW , Kilonzo SB , Manyiri PM , Peck RN , Mazigo HD , 2020. Morbidity and mortality due to Schistosoma mansoni related periportal fibrosis: could early diagnosis of varices improve the outcome following available treatment modalities in sub Saharan Africa? A scoping review. Trop Med Infect Dis 5: 20.
-
6.
Petroianu A , De Oliveira AE , Alberti LR , 2005. Hypersplenism in schistosomatic portal hypertension. Arch Med Res 36: 496–501.
-
7.
Abebe N , Erko B , Medhin G , Berhe N , 2014. Clinico-epidemiological study of Schistosomiasis mansoni in Waja-Timuga, District of Alamata, northern Ethiopia. Parasit Vectors 7: 158.
-
8.
Ruiz-Guevara R , Noya BAD , Valero SK , Lecuna P , Garassini M , Noya O , 2007. Clinical and ultrasound findings before and after praziquantel treatment among Venezuelan schistosomiasis patients. Rev Soc Bras Med Trop 40: 505–511.
-
9.
Richter J , 2000. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop 77: 111–131.
-
10.
Tamarozzi F , Fittipaldo VA , Orth HM , Richter J , Buonfrate D , Riccardi N , Gobbi FG , 2021. Diagnosis and clinical management of hepatosplenic schistosomiasis: a scoping review of the literature. PLoS Negl Trop Dis 15: e0009191.
-
11.
Rodrigues SG , Mendoza YP , Bosch J , 2019. Beta blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep 2: 100063.
-
12.
do Vale GT , Ceron CS , Gonzaga NA , Simplicio JA , Padovan JC , 2019. Three generations of β-blockers: history, class differences and clinical applicability. Curr Hypertens Rev 15: 22–31.
-
13.
Reiter MJ , 2004. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis 47: 11–33.
-
14.
Prichard BN , 1964. Hypotensive action of pronethalol. BMJ 1: 1227–1228.
-
15.
Frishman WH , 2016. Beta-adrenergic receptor blockers in hypertension: alive and well. Prog Cardiovasc Dis 59: 247–252.
-
16.
Sauerbruch T , Hennenberg M , Trebicka J , Schierwagen R , 2022. Beta-blockers in patients with liver cirrhosis: pragmatism or perfection? Front Med (Lausanne) 9: 1100966.
-
17.
Jothimani D , Rela M , Kamath PS , 2023. Liver cirrhosis and portal hypertension: how to deal with esophageal varices? Med Clin North Am 107: 491–504.
-
18.
Razafindrazoto CI , Razafindrabekoto LDE , Hasina Laingonirina DH , Raveloson R , Rasolonjatovo AS , Rakotozafindrabe ALR , Rabenjanahary TH , Razafimahefa SH , Ramanampamonjy RM , 2022. Carvedilol versus propranolol in the prevention of variceal rebleeding in hepatosplenic schistosomiasis: efficacy and safety. JGH Open 6: 213–218.
-
19.
Garcia-Tsao G , Bosch J , 2010. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 362: 823–832.
-
20.
Pascal JP , Cales P , 1987. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 317: 856–861.
-
21.
Lebrec D , Poynard T , Hillon P , Benhamou JP , 1981. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 305: 1371–1374.
-
22.
Gauthier C , Langin D , Balligand JL , 2000. Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21: 426–431.
-
23.
Lebrec D , Nouel O , Corbic M , Benhamou JP , 1980. Propranolol: a medical treatment for portal hypertension? Lancet 2: 180–182.
-
24.
Villanueva C et al., 2009. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterol 137: 119–128.
-
25.
Abraldes JG , Tarantino I , Turnes J , Garcia-Pagan JC , Rodes J , Bosch J , 2003. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatol 37: 902–908.
-
26.
D’Amico G , Garcia-Pagan JC , Luca A , Bosch J , 2006. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterol 131: 1611–1624.
-
27.
Reiberger T et al., 2013. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62: 1634–1641.
-
28.
Turnes J , Garcia-Pagan JC , Abraldes JG , Hernandez-Guerra M , Dell’Era A , Bosch J , 2006. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 101: 506–512.
-
29.
Albillos A , Bañares R , González M , Ripoll C , Gonzalez R , Catalina MV , Molinero LM , 2007. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 102: 1116–1126.
-
30.
Michel MC , 2020. α(1)-Adrenoceptor activity of β-adrenoceptor ligands: an expected drug property with limited clinical relevance. Eur J Pharmacol 889: 173632.
-
31.
Koshimizu TA , Tsujimoto G , Hirasawa A , Kitagawa Y , Tanoue A , 2004. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res 63: 662–672.
-
32.
Gehr TW , Tenero DM , Boyle DA , Qian Y , Sica DA , Shusterman NH , 1999. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 55: 269–277.
-
33.
Villanueva C et al., 2019. β Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393: 1597–1608.
-
34.
Rasool MF , Khalil F , Läer S , 2017. Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based pharmacokinetic modeling approach. Eur J Drug Metab Pharmacokinet 42: 383–396.
-
35.
Kim IM , Tilley DG , Chen J , Salazar NC , Whalen EJ , Violin JD , Rockman HA , 2008. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 105: 14555–14560.
-
36.
Carr R 3rd et al., 2016. β-Arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction. Proc Natl Acad Sci USA 113: E4107–E4116.
-
37.
Ryba DM , Li J , Cowan CL , Russell B , Wolska BM , Solaro RJ , 2017. Long-term biased β-arrestin signaling improves cardiac structure and function in dilated cardiomyopathy. Circulation 135: 1056–1070.
-
38.
Bond RA , Lucero Garcia-Rojas EY , Hegde A , Walker JKL , 2019. Therapeutic potential of targeting β-arrestin. Front Pharmacol 10: 124.
-
39.
Lefkowitz RJ , Shenoy SK , 2005. Transduction of receptor signals by beta-arrestins. Science 308: 512–517.
-
40.
Hennenberg M , Trebicka J , Sauerbruch T , Heller J , 2008. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 57: 1300–1314.
-
41.
Lovgren AK et al., 2011. β-Arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. Sci Transl Med 3: 74ra23.
-
42.
Gu YJ , Sun WY , Zhang S , Wu JJ , Wei W , 2015. The emerging roles of β-arrestins in fibrotic diseases. Acta Pharmacol Sin 36: 1277–1287.
-
43.
Wisler JW , Dewire SM , Whalen EJ , Violin JD , Drake MT , Ahn S , Shenoy SK , Lefkowitz RJ , 2007. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci USA 104: 16657–16662.
-
44.
Alexander SPH et al., 2021. The concise guide to pharmacology 2021/22: G protein‐coupled receptors. Br J Pharmacol 178: S27–S156.
-
45.
Lashen SA , Shamseya MM , Madkour MA , Abdel Salam RM , Mostafa SS , 2022. β-Arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: a prospective study. World J Hepatol 14: 429–441.
-
46.
Groszmann RJ et al., for the Portal Hypertension Collaborative Group , 2005. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353: 2254–2261.
-
47.
de Franchis R , Bosch J , Garcia-Tsao G , Reiberger T , Ripoll C , for the Baveno VII Faculty , 2022. Baveno VII: renewing consensus in portal hypertension. J Hepatol 76: 959–974.
-
48.
Sørensen M , Larsen LP , Villadse GE , Aagaard NK , Grønbæk H , Keiding S , Vilstrup H , 2019. β-Blockers improve presinusoidal portal hypertension. Dig Dis Sci 63: 3153–3157.
-
49.
Turco L , Garcia-Tsao G , 2019. Portal hypertension: pathogenesis and diagnosis. Clin Liver Dis 23: 573–587.
-
50.
Bosch J , Garcia-Pagan JC , Schiff ER , Maddrey WC , Sorrell MF, eds. Schiff’s Diseases of the Liver, 10th edition. Hoboken, NJ: Wiley-Blackwell, 419–448.
-
51.
Ginès P , Krag A , Abraldes JG , Solà E , Fabrellas N , Kamath PS , 2021. Liver cirrhosis. Lancet 398: 1359–1376.
-
52.
Asrani SK , Devarbhavi H , Eaton J , Kamath PS , 2019. Burden of liver diseases in the world. J Hepatol 70: 151–171.
-
53.
Yoshiji H et al., 2021. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol 56: 593–619.
-
54.
Lambertucci JR , 2014. Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools. Rev Soc Bras Med Trop 47: 130–136.
-
55.
Ferrari TC , Moreira PR , 2011. Neuroschistosomiasis: clinical symptoms and pathogenesis. Lancet Neurol 10: 853–864.
-
56.
Strauss E , 2002. Hepatosplenic schistosomiasis: a model for the study of portal hypertension. Ann Hepatol 1: 6–11.
-
57.
de Carvalho BT , Coutinho Domingues AL , de Almeida Lopes EP , Brandão SC , 2016. Increased hepatic arterial blood flow measured by hepatic perfusion index in hepatosplenic schistosomiasis: new concepts for an old disease. Dig Dis Sci 61: 2118–2126.
-
58.
Farias AQ , Kassab F , Da Rocha ECV , Dos Santos Bomfim VL , Vezozzo DCP , Bittencourt PL , Carrilho FJ , 2009. Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension. J Gastroenterol Hepatol 24: 1852–1856.
-
59.
Sinkala E , Vinikoor M , Zyambo K , Besa E , Nsokolo B , Kelly P , 2020. Propranolol reduces portal vein diameter in schistosomal liver disease with portal hypertension: a prospective cohort study. Am J Trop Med Hyg 102: 832–837.
-
60.
Kong DR , 2013. Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. World J Gastroenterol 19: 4228–4233.
-
61.
el Tourabi H , el Amin AA , Shaheen M , Woda SA , Homeida M , Harron DW , 1994. Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. Ann Trop Med Parasitol 88: 493–500.
-
62.
de Abreu ES , Nardelli MJ , Lima AMC , Cardoso JB , Osório FMF , Ferrari TCA , Faria LC , Couto CA , Cançado GGL , 2022. Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. Trans R Soc Trop Med Hyg 116: 663–667.
-
63.
Sarin SK , Groszmann RJ , Mosca PG , Rojkind M , Stadecker MJ , Bhatnagar R , Reuben A , Dayal Y , 1991. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest 87: 1032–1036.
-
64.
el-Aggan HA , Abd el-Kader M , el-Gebaly WM , 1992. Schistosomal nephropathy: effect of ciclosporin A (CsA) in murine schistosomiasis mansoni. J Egypt Soc Parasitol 22: 205–216.
-
65.
Dowidar N , Hafez A , Abdel Baki M , 2005. Endoscopic sclerotherapy of oesophageal varices due to hepatosplenic schistosomiasis: a randomized controlled trial evaluating the effect of adjuvant propranolol therapy. J Egypt Soc Parasitol 35: 773–786.
-
66.
Homeida M , Ali H , Arbab B , Harron D , 1987. Propranolol disposition in patients with hepatosplenic schistosomiasis. Br J Clin Pharmacol 24: 393–396.
-
67.
Mies S , Pereira Mde B , Orlando CD , Sette M , Raia S , 1988. Propranolol in the prevention of recurrence of digestive hemorrhage in patients with hepatosplenic schistosomiasis. AMB Rev Assoc Med Bras 34: 24–28.
-
68.
Mies S , Neto OB , Beer A Jr , Baía CE , Alfieri F Jr , Pereira LM , Sette MJ , Raia S , 1997. Systemic and hepatic hemodynamics in hepatosplenic Manson’s schistosomiasis with and without propranolol. Dig Dis Sci 42: 751–761.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1582 | 1582 | 47 |
| Full Text Views | 62 | 62 | 1 |
| PDF Downloads | 76 | 76 | 1 |
β-Blockers in Hepatosplenic Schistosomiasis: A Narrative Review
Fernanda Alves Gelape
Fernanda Alves Gelape
Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil;
Search for other papers by Fernanda Alves Gelape in
Current site
Google Scholar
PubMed
Search for other papers by Fernanda Alves Gelape in
Current site
Google Scholar
PubMed
Claudia Alves Couto
Claudia Alves Couto
Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil;
Search for other papers by Claudia Alves Couto in
Current site
Google Scholar
PubMed
Search for other papers by Claudia Alves Couto in
Current site
Google Scholar
PubMed
Guilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil;
Hospital da Polícia Militar de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for other papers by Guilherme Grossi Lopes Cançado in
Current site
Google Scholar
PubMed
Hospital da Polícia Militar de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
Search for other papers by Guilherme Grossi Lopes Cançado in
Current site
Google Scholar
PubMed
ABSTRACT.
Hepatosplenic schistosomiasis (HSS) is a serious complication of chronic schistosomiasis that can result in portal hypertension and variceal bleeding. β-blockers, a class of medications commonly used to treat hypertension and other cardiovascular conditions, have been investigated for their potential use in preventing variceal bleeding in HSS. Several studies have shown that β-blockers can reduce portal pressure and prevent variceal bleeding effectively in these patients. However, there are limited data on the long-term efficacy and safety of β-blockers in this setting, and further research is needed to determine the optimal use of these medications. This review summarizes the evidence supporting current recommendations of β-blocker use in patients with HSS.
Author Notes
Financial support: We acknowledge the financial support of the Pró-Reitoria de Pesquisa da Universidade Federal de Minas Gerais.
Authors’ addresses: Fernanda Gelape, Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, E-mail: fernandagelape@hotmail.com. Claudia Alves Couto, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, E-mail: clalcouto@gmail.com. Guilherme Grossi Lopes Cançado, Hospital das Clínicas da Universidade Federal de Minas Gerais, and Hospital da Polícia Militar de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, E-mail: guilhermegrossi@terra.com.br.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization , 2021. Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021–2030. Available at: https://www.who.int/publications/i/item/9789240010352. Accessed May 12, 2023.
-
2.
World Health Organization , 2013. Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2020. Available at: https://apps.who.int/iris/handle/10665/78074. Accessed May 12, 2023.
-
3.
Institute for Health Metrics and Evaluation , 2019. Schistosomiasis: Level 3 Cause. Available at: https://www.healthdata.org/results/gbd_summaries/2019/schistosomiasis-level-3-cause. Accessed March 31, 2023.
-
4.
Montresor A , Mwinzi P , Mupfasoni D , Garba A , 2022. Reduction in DALYs lost due to soil-transmitted helminthiases and schistosomiasis from 2000 to 2019 is parallel to the increase in coverage of the global control programmes. PLoS Negl Trop Dis 16: e0010575.
-
5.
Gunda DW , Kilonzo SB , Manyiri PM , Peck RN , Mazigo HD , 2020. Morbidity and mortality due to Schistosoma mansoni related periportal fibrosis: could early diagnosis of varices improve the outcome following available treatment modalities in sub Saharan Africa? A scoping review. Trop Med Infect Dis 5: 20.
-
6.
Petroianu A , De Oliveira AE , Alberti LR , 2005. Hypersplenism in schistosomatic portal hypertension. Arch Med Res 36: 496–501.
-
7.
Abebe N , Erko B , Medhin G , Berhe N , 2014. Clinico-epidemiological study of Schistosomiasis mansoni in Waja-Timuga, District of Alamata, northern Ethiopia. Parasit Vectors 7: 158.
-
8.
Ruiz-Guevara R , Noya BAD , Valero SK , Lecuna P , Garassini M , Noya O , 2007. Clinical and ultrasound findings before and after praziquantel treatment among Venezuelan schistosomiasis patients. Rev Soc Bras Med Trop 40: 505–511.
-
9.
Richter J , 2000. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies. Acta Trop 77: 111–131.
-
10.
Tamarozzi F , Fittipaldo VA , Orth HM , Richter J , Buonfrate D , Riccardi N , Gobbi FG , 2021. Diagnosis and clinical management of hepatosplenic schistosomiasis: a scoping review of the literature. PLoS Negl Trop Dis 15: e0009191.
-
11.
Rodrigues SG , Mendoza YP , Bosch J , 2019. Beta blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep 2: 100063.
-
12.
do Vale GT , Ceron CS , Gonzaga NA , Simplicio JA , Padovan JC , 2019. Three generations of β-blockers: history, class differences and clinical applicability. Curr Hypertens Rev 15: 22–31.
-
13.
Reiter MJ , 2004. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis 47: 11–33.
-
14.
Prichard BN , 1964. Hypotensive action of pronethalol. BMJ 1: 1227–1228.
-
15.
Frishman WH , 2016. Beta-adrenergic receptor blockers in hypertension: alive and well. Prog Cardiovasc Dis 59: 247–252.
-
16.
Sauerbruch T , Hennenberg M , Trebicka J , Schierwagen R , 2022. Beta-blockers in patients with liver cirrhosis: pragmatism or perfection? Front Med (Lausanne) 9: 1100966.
-
17.
Jothimani D , Rela M , Kamath PS , 2023. Liver cirrhosis and portal hypertension: how to deal with esophageal varices? Med Clin North Am 107: 491–504.
-
18.
Razafindrazoto CI , Razafindrabekoto LDE , Hasina Laingonirina DH , Raveloson R , Rasolonjatovo AS , Rakotozafindrabe ALR , Rabenjanahary TH , Razafimahefa SH , Ramanampamonjy RM , 2022. Carvedilol versus propranolol in the prevention of variceal rebleeding in hepatosplenic schistosomiasis: efficacy and safety. JGH Open 6: 213–218.
-
19.
Garcia-Tsao G , Bosch J , 2010. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 362: 823–832.
-
20.
Pascal JP , Cales P , 1987. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 317: 856–861.
-
21.
Lebrec D , Poynard T , Hillon P , Benhamou JP , 1981. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med 305: 1371–1374.
-
22.
Gauthier C , Langin D , Balligand JL , 2000. Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21: 426–431.
-
23.
Lebrec D , Nouel O , Corbic M , Benhamou JP , 1980. Propranolol: a medical treatment for portal hypertension? Lancet 2: 180–182.
-
24.
Villanueva C et al., 2009. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterol 137: 119–128.
-
25.
Abraldes JG , Tarantino I , Turnes J , Garcia-Pagan JC , Rodes J , Bosch J , 2003. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatol 37: 902–908.
-
26.
D’Amico G , Garcia-Pagan JC , Luca A , Bosch J , 2006. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterol 131: 1611–1624.
-
27.
Reiberger T et al., 2013. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 62: 1634–1641.
-
28.
Turnes J , Garcia-Pagan JC , Abraldes JG , Hernandez-Guerra M , Dell’Era A , Bosch J , 2006. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 101: 506–512.
-
29.
Albillos A , Bañares R , González M , Ripoll C , Gonzalez R , Catalina MV , Molinero LM , 2007. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 102: 1116–1126.
-
30.
Michel MC , 2020. α(1)-Adrenoceptor activity of β-adrenoceptor ligands: an expected drug property with limited clinical relevance. Eur J Pharmacol 889: 173632.
-
31.
Koshimizu TA , Tsujimoto G , Hirasawa A , Kitagawa Y , Tanoue A , 2004. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res 63: 662–672.
-
32.
Gehr TW , Tenero DM , Boyle DA , Qian Y , Sica DA , Shusterman NH , 1999. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 55: 269–277.
-
33.
Villanueva C et al., 2019. β Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393: 1597–1608.
-
34.
Rasool MF , Khalil F , Läer S , 2017. Optimizing the clinical use of carvedilol in liver cirrhosis using a physiologically based pharmacokinetic modeling approach. Eur J Drug Metab Pharmacokinet 42: 383–396.
-
35.
Kim IM , Tilley DG , Chen J , Salazar NC , Whalen EJ , Violin JD , Rockman HA , 2008. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 105: 14555–14560.
-
36.
Carr R 3rd et al., 2016. β-Arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction. Proc Natl Acad Sci USA 113: E4107–E4116.
-
37.
Ryba DM , Li J , Cowan CL , Russell B , Wolska BM , Solaro RJ , 2017. Long-term biased β-arrestin signaling improves cardiac structure and function in dilated cardiomyopathy. Circulation 135: 1056–1070.
-
38.
Bond RA , Lucero Garcia-Rojas EY , Hegde A , Walker JKL , 2019. Therapeutic potential of targeting β-arrestin. Front Pharmacol 10: 124.
-
39.
Lefkowitz RJ , Shenoy SK , 2005. Transduction of receptor signals by beta-arrestins. Science 308: 512–517.
-
40.
Hennenberg M , Trebicka J , Sauerbruch T , Heller J , 2008. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 57: 1300–1314.
-
41.
Lovgren AK et al., 2011. β-Arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. Sci Transl Med 3: 74ra23.
-
42.
Gu YJ , Sun WY , Zhang S , Wu JJ , Wei W , 2015. The emerging roles of β-arrestins in fibrotic diseases. Acta Pharmacol Sin 36: 1277–1287.
-
43.
Wisler JW , Dewire SM , Whalen EJ , Violin JD , Drake MT , Ahn S , Shenoy SK , Lefkowitz RJ , 2007. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci USA 104: 16657–16662.
-
44.
Alexander SPH et al., 2021. The concise guide to pharmacology 2021/22: G protein‐coupled receptors. Br J Pharmacol 178: S27–S156.
-
45.
Lashen SA , Shamseya MM , Madkour MA , Abdel Salam RM , Mostafa SS , 2022. β-Arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: a prospective study. World J Hepatol 14: 429–441.
-
46.
Groszmann RJ et al., for the Portal Hypertension Collaborative Group , 2005. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353: 2254–2261.
-
47.
de Franchis R , Bosch J , Garcia-Tsao G , Reiberger T , Ripoll C , for the Baveno VII Faculty , 2022. Baveno VII: renewing consensus in portal hypertension. J Hepatol 76: 959–974.
-
48.
Sørensen M , Larsen LP , Villadse GE , Aagaard NK , Grønbæk H , Keiding S , Vilstrup H , 2019. β-Blockers improve presinusoidal portal hypertension. Dig Dis Sci 63: 3153–3157.
-
49.
Turco L , Garcia-Tsao G , 2019. Portal hypertension: pathogenesis and diagnosis. Clin Liver Dis 23: 573–587.
-
50.
Bosch J , Garcia-Pagan JC , Schiff ER , Maddrey WC , Sorrell MF, eds. Schiff’s Diseases of the Liver, 10th edition. Hoboken, NJ: Wiley-Blackwell, 419–448.
-
51.
Ginès P , Krag A , Abraldes JG , Solà E , Fabrellas N , Kamath PS , 2021. Liver cirrhosis. Lancet 398: 1359–1376.
-
52.
Asrani SK , Devarbhavi H , Eaton J , Kamath PS , 2019. Burden of liver diseases in the world. J Hepatol 70: 151–171.
-
53.
Yoshiji H et al., 2021. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol 56: 593–619.
-
54.
Lambertucci JR , 2014. Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools. Rev Soc Bras Med Trop 47: 130–136.
-
55.
Ferrari TC , Moreira PR , 2011. Neuroschistosomiasis: clinical symptoms and pathogenesis. Lancet Neurol 10: 853–864.
-
56.
Strauss E , 2002. Hepatosplenic schistosomiasis: a model for the study of portal hypertension. Ann Hepatol 1: 6–11.
-
57.
de Carvalho BT , Coutinho Domingues AL , de Almeida Lopes EP , Brandão SC , 2016. Increased hepatic arterial blood flow measured by hepatic perfusion index in hepatosplenic schistosomiasis: new concepts for an old disease. Dig Dis Sci 61: 2118–2126.
-
58.
Farias AQ , Kassab F , Da Rocha ECV , Dos Santos Bomfim VL , Vezozzo DCP , Bittencourt PL , Carrilho FJ , 2009. Propranolol reduces variceal pressure and wall tension in schistosomiasis presinusoidal portal hypertension. J Gastroenterol Hepatol 24: 1852–1856.
-
59.
Sinkala E , Vinikoor M , Zyambo K , Besa E , Nsokolo B , Kelly P , 2020. Propranolol reduces portal vein diameter in schistosomal liver disease with portal hypertension: a prospective cohort study. Am J Trop Med Hyg 102: 832–837.
-
60.
Kong DR , 2013. Effects of propranolol or propranolol plus isosorbide-5-mononitrate on variceal pressure in schistosomiasis. World J Gastroenterol 19: 4228–4233.
-
61.
el Tourabi H , el Amin AA , Shaheen M , Woda SA , Homeida M , Harron DW , 1994. Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. Ann Trop Med Parasitol 88: 493–500.
-
62.
de Abreu ES , Nardelli MJ , Lima AMC , Cardoso JB , Osório FMF , Ferrari TCA , Faria LC , Couto CA , Cançado GGL , 2022. Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. Trans R Soc Trop Med Hyg 116: 663–667.
-
63.
Sarin SK , Groszmann RJ , Mosca PG , Rojkind M , Stadecker MJ , Bhatnagar R , Reuben A , Dayal Y , 1991. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest 87: 1032–1036.
-
64.
el-Aggan HA , Abd el-Kader M , el-Gebaly WM , 1992. Schistosomal nephropathy: effect of ciclosporin A (CsA) in murine schistosomiasis mansoni. J Egypt Soc Parasitol 22: 205–216.
-
65.
Dowidar N , Hafez A , Abdel Baki M , 2005. Endoscopic sclerotherapy of oesophageal varices due to hepatosplenic schistosomiasis: a randomized controlled trial evaluating the effect of adjuvant propranolol therapy. J Egypt Soc Parasitol 35: 773–786.
-
66.
Homeida M , Ali H , Arbab B , Harron D , 1987. Propranolol disposition in patients with hepatosplenic schistosomiasis. Br J Clin Pharmacol 24: 393–396.
-
67.
Mies S , Pereira Mde B , Orlando CD , Sette M , Raia S , 1988. Propranolol in the prevention of recurrence of digestive hemorrhage in patients with hepatosplenic schistosomiasis. AMB Rev Assoc Med Bras 34: 24–28.
-
68.
Mies S , Neto OB , Beer A Jr , Baía CE , Alfieri F Jr , Pereira LM , Sette MJ , Raia S , 1997. Systemic and hepatic hemodynamics in hepatosplenic Manson’s schistosomiasis with and without propranolol. Dig Dis Sci 42: 751–761.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1582 | 1582 | 47 |
| Full Text Views | 62 | 62 | 1 |
| PDF Downloads | 76 | 76 | 1 |